|
1
|
Saini S: PSA and beyond: Alternative
prostate cancer biomarkers. Cell Oncol (Dordr). 39:97–106. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lei T, Mao WM, Yang HJ, Chen XZ, Lei TH,
Wang XH, Ying Q, Chen WQ and Zhang SW: Study on cancer incidence
through the cancer registry program in 11 cities and counties,
China. Zhonghua Liu Xing Bing Xue Za Zhi. 30:1165–1170. 2009.(In
Chinese). PubMed/NCBI
|
|
4
|
Fong MK, Hare R and Jarkowski A: A new era
for castrate resistant prostate cancer: A treatment review and
update. J Oncol Pharm Pract. 18:343–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rodrigues DN, Butler LM, Estelles DL and
de Bono JS: Molecular pathology and prostate cancer therapeutics:
From biology to bedside. J Pathol. 232:178–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lilja H: Testing new PSA subforms to
enhance the accuracy of predicting cancer risk and disease outcome
in prostate cancer. Clin Chem. 54:1248–1249. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lilja H, Ulmert D and Vickers AJ:
Prostate-specific antigen and prostate cancer: Prediction,
detection and monitoring. Nat Rev Cancer. 8:268–278. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Romero Otero J, Garcia Gomez B, Campos
Juanatey F and Touijer KA: Prostate cancer biomarkers: An update.
Urol Oncol. 32:252–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cary KC and Cooperberg MR: Biomarkers in
prostate cancer surveillance and screening: Past, present, and
future. Ther Adv Urol. 5:318–329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Prensner JR, Rubin MA, Wei JT and
Chinnaiyan AM: Beyond PSA: The next generation of prostate cancer
biomarkers. Sci Transl Med. 4:127rv32012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Voorhees PM, Dees EC, O'Neil B and
Orlowski RZ: The proteasome as a target for cancer therapy. Clin
Cancer Res. 9:6316–6325. 2003.PubMed/NCBI
|
|
12
|
Ciechanover A: The ubiquitin-proteasome
pathway: On protein death and cell life. EMBO J. 17:7151–7160.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stoebner PE, Lavabre-Bertrand T, Henry L,
Guiraud I, Carillo S, Dandurand M, Joujoux JM, Bureau JP and
Meunier L: High plasma proteasome levels are detected in patients
with metastatic malignant melanoma. Br J Dermatol. 152:948–953.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang H, Zhou P, Huang H, Chen D, Ma N, Cui
QC, Shen S, Dong W, Zhang X, Lian W, et al: Shikonin exerts
antitumor activity via proteasome inhibition and cell death
induction in vitro and in vivo. Int J Cancer. 124:2450–2459. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Piantanelli L, Zaia A, Rossolini G,
Piantanelli A, Basso A and Anisimov VN: Long-live euthymic
BALB/c-nu mice. I. Survival study suggests body weight as a life
span predictor. Mech Ageing Dev. 122:463–475. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
An B, Goldfarb RH, Siman R and Dou QP:
Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective
function and selectively accumulate the cyclin-dependent kinase
inhibitor p27 and induce apoptosis in transformed, but not normal,
human fibroblasts. Cell Death Differ. 5:1062–1075. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harmelin A, Danon T, Kela I and Brenner O:
Biopsy of the mouse prostate. Lab Anim. 39:215–220. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wada M, Kosaka M, Saito S, Sano T, Tanaka
K and Ichihara A: Serum concentration and localization in tumor
cells of proteasomes in patients with hematologic malignancy and
their pathophysiologic significance. J Lab Clin Med. 121:215–223.
1993.PubMed/NCBI
|
|
19
|
Lavabre-Bertrand T, Henry L, Carillo S,
Guiraud I, Ouali A, Dutaud D, Aubry L, Rossi JF and Bureau JP:
Plasma proteasome level is a potential marker in patients with
solid tumors and hemopoietic malignancies. Cancer. 92:2493–2500.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dutaud D, Aubry L, Henry L, Levieux D,
Hendil KB, Kuehn L, Bureau JP and Ouali A: Development and
evaluation of a sandwich ELISA for quantification of the 20S
proteasome in human plasma. J Immunol Methods. 260:183–193. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Egerer K, Kuckelkorn U, Rudolph PE,
Rückert JC, Dörner T, Burmester GR, Kloetzel PM and Feist E:
Circulating proteasomes are markers of cell damage and immunologic
activity in autoimmune diseases. J Rheumatol. 29:2045–2052.
2002.PubMed/NCBI
|
|
22
|
Goldberg AL: Functions of the proteasome:
The lysis at the end of the tunnel. Science. 268:522–523. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dou QP and Li B: Proteasome inhibitors as
potential novel anticancer agents. Drug Resist Updat. 2:215–223.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. Part.
1:Screening, diagnosis and local treatment with curative
intent–update 2013. Eur Urol 65: 124–137. 2014.
|
|
26
|
Ma W, Kantarjian H, Bekele B, Donahue AC,
Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, et al:
Proteasome enzymatic activities in plasma as risk stratification of
patients with acute myeloid leukemia and advanced-stage
myelodysplastic syndrome. Clin Cancer Res. 15:3820–3826. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fowler FJ Jr, Barry MJ, Walker-Corkery B,
Caubet JF, Bates DW, Lee JM, Hauser A and McNaughton-Collins M: The
impact of a suspicious prostate biopsy on patients' psychological,
socio-behavioral, and medical care outcomes. J Gen Intern Med.
21:715–721. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deng X, Zhou P, Wei X, Uhlman M, Lin Y,
Lin X, Wu S, Diao P, Xie H, Liu J, et al: Plasma proteasomal
chymotrypsin-like activity correlates with prostate cancer
progression. Tumour Biol. 36:4115–4121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Frankland-Searby S and Bhaumik SR: The 26S
proteasome complex: An attractive target for cancer therapy.
Biochim Biophys Acta. 1825:64–76. 2012.PubMed/NCBI
|
|
30
|
Adams J: The proteasome: Structure,
function, and role in the cell. Cancer Treat Rev. 29 Suppl 1:S3–S9.
2003. View Article : Google Scholar
|
|
31
|
Jeremias I, Kupatt C, Baumann B, Herr I,
Wirth T and Debatin KM: Inhibition of nuclear factor kappaB
activation attenuates apoptosis resistance in lymphoid cells.
Blood. 91:4624–4631. 1998.PubMed/NCBI
|
|
32
|
Patel NM, Nozaki S, Shortle NH,
Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet
RJ Jr, Sledge GW Jr and Nakshatri H: Paclitaxel sensitivity of
breast cancer cells with constitutively active NF-kappaB is
enhanced by IkappaBalpha super-repressor and parthenolide.
Oncogene. 19:4159–4169. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen D and Dou QP: The
ubiquitin-proteasome system as a prospective molecular target for
cancer treatment and prevention. Curr Protein Pept Sci. 11:459–470.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Almond JB and Cohen GM: The proteasome: A
novel target for cancer chemotherapy. Leukemia. 16:433–443. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li B and Dou QP: Bax degradation by the
ubiquitin/proteasome-dependent pathway: Involvement in tumor
survival and progression. Proc Natl Acad Sci USA. 97:pp. 3850–3855.
2000; View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kondakova IV, Spirina LV, Koval VD,
Shashova EE, Choinzonov EL, Ivanova EV, Kolomiets LA, Chernyshova
AL, Slonimskaya EM, Usynin EA and Afanasyev SG: Chymotripsin-like
activity and subunit composition of proteasomes in human cancers.
Mol Biol (Mosk). 48:444–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oldziej A, Bolkun L, Galar M, Kalita J,
Ostrowska H, Romaniuk W and Kloczko J: Assessment of proteasome
concentration and chymotrypsin-like activity in plasma of patients
with newly diagnosed multiple myeloma. Leuk Res. 38:925–930. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Krawczuk-Rybak M, Leszczynska E,
Malinowska I, Matysiak M and Ostrowska H: Proteasome
chymotrypsin-like activity in plasma as a useful marker for
children with acute lymphoblastic leukemia. Scand J Clin Lab
Invest. 72:67–72. 2012. View Article : Google Scholar : PubMed/NCBI
|
